Pharmacokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function

被引：0
|
作者：
J. F. W. Hoogkamer
C. H. Kleinbloesem
M. Ouwerkerk
A. Högemann
A. Nokhodian
W. Kirch
E. Weidekamm
机构：
[1] Clin-Pharma Research,
[2] CH-4127 Birsfelden,undefined
[3] Switzerland Tel.: +41-61-313 3220; Fax: +41-61-313 3242,undefined
[4] Takeda Euro Research and Development Centre,undefined
[5] Frankfurt am Main,undefined
[6] Germany,undefined
[7] Medizinische Fakultät Technische Universität Dresden,undefined
[8] Dresden,undefined
[9] Germany,undefined
来源：
European Journal of Clinical Pharmacology | 1998年 / 54卷
关键词：
Key words Candesartan; Hepatic impairment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: The influence of liver disease on the pharmacokinetics of candesartan, a long-acting selective AT1 subtype angiotensin II receptor antagonist was studied.
引用
收藏
页码：341 / 345
页数：4
相关论文
共 50 条
  • [41] PHARMACOKINETICS OF METIOPRIM IN NORMAL SUBJECTS AND PATIENTS WITH IMPAIRED RENAL-FUNCTION
    VERGIN, H
    BISHOPFREUDLING, GB
    KAISER, W
    KOHLER, M
    STROBEL, K
    REUTTER, FW
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 24 (02) : 190 - 193
  • [42] Safety and pharmacokinetics of DUR-928 in hepatic function impaired subjects
    Shah, Jaymin
    Pozo, Katherine
    Scott, Deborah
    Lin, WeiQi
    JOURNAL OF HEPATOLOGY, 2021, 75 : S613 - S613
  • [43] AN OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND PHARMACOKINETICS OF AT1001 IN SUBJECTS WITH IMPAIRED RENAL FUNCTION AND HEALTHY SUBJECTS WITH NORMAL RENAL FUNCTION
    Johnson, F. K.
    Mudd, P. N., Jr.
    Sitaraman, S.
    Boudes, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S85 - S85
  • [44] An Open-Label Study to Determine the Pharmacokinetics and Safety of Migalastat HCl in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function
    Johnson, Franklin K.
    Mudd, Paul N., Jr.
    DiMino, Tara
    Vosk, Jennie
    Sitaraman, Sheela
    Boudes, Pol
    France, Nicholas
    Barlow, Carrolee
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (04): : 256 - 261
  • [45] Pharmacokinetics and safety of GST-HG171, a novel 3CL protease inhibitor, in Chinese subjects with impaired and normal liver function
    Zhou, Jing
    Zhang, Hong
    Chen, Hong
    Zhang, George
    Mao, John
    Zhang, Tianxiang
    Tang, Yanan
    Yan, Wenhao
    Li, Chuanjing
    Ding, Yanhua
    Jin, Qinglong
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (08)
  • [46] Pharmacokinetics of a new fixed-dose combination of candesartan cilexetil, hydrochlorothiazide, and rosuvastatin in healthy adult subjects
    Yerino, Gustavo A.
    Feleder, Ethel C.
    Halabe, Emilia K.
    Diaz, Liliana
    Sakson, Mario
    Iglesias, Mariana
    Haddad, Tobias
    Roldan, Emilio
    Mondelo, Nelida
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2022, 60 (04) : 192 - 206
  • [47] Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Normal or Varying Degrees of Impaired Renal Function
    Mayer M.
    Nudurupati S.
    Peng X.
    Marcinak J.
    Drugs in R&D, 2014, 14 (4) : 273 - 282
  • [48] Single and multiple dose pharmacokinetics of candesartan cilexetil in healthy volunteers
    Riddell, JG
    Högemann, AM
    JOURNAL OF HYPERTENSION, 1998, 16 : S243 - S243
  • [49] Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis
    Pfister, M
    Schaedeli, F
    Frey, FJ
    Uehlinger, DE
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (06) : 645 - 651
  • [50] Pharmacokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function
    Buur, T
    Larsson, R
    Berglund, U
    Donat, F
    Tronquet, C
    JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (02): : 108 - 115
12345